1 January 2025 in Research
Malignant tumors constitute a major global public health burden. Chronic psychological stress (CPS) manifests as sustained dysregulation arising from prolonged adaptive responses to chronic endogenous and exogenous stimuli. Clinical evidence indicates that CPS markedly influences cancer progression, with most oncology patients developing detectable stress-related psychological disorders during disease management. This review synthesizes recent advances in understanding CPS-mediated oncogenic mechanisms and evaluates current intervention approaches. Mechanistically, CPS compromises immune surveillance through neuroendocrine-mediated hormonal dysregulation, impairing malignant cell recognition and clearance. Concurrently, CPS hormones promote tumor metabolic adaptation via hypothalamic–pituitary–adrenal axis-driven metabolic reprogramming, enhancing glycolytic flux to support uncontrolled proliferation. CPS further accelerates tumor progression through reactive oxygen species-induced mitochondrial impairment, DNA damage accumulation, and inflammatory cascades. Notably, CPS induces gut microbiota perturbations that reciprocally amplify tumorigenic processes through microbial metabolite disturbances and neuroimmune crosstalk, creating a self-perpetuating pathogenic loop. Therapeutic strategies to address cancer-related CPS that encompass pharmacological agents targeting neuroendocrine pathways, psychosomatic behavioral interventions, social environment adjustments, and evidence-based traditional Chinese medicine formulations demonstrate potential in cancer prevention, treatment, and outcome optimization. However, challenges remain in achieving precise neuromodulation and minimizing intervention side effects, underscoring the need for mechanism-guided therapeutic innovations.
3 February 2026 in Cell Death & Disease
Recurrence and metastasis are the main causes of death in ovarian cancer (OC). Long non-coding RNAs (lncRNAs) are considered as good prognostic models and potential therapeutic targets for cancer patients because of their easy detection and strong correlation. Our study identifies an OC-associated lncRNA with tumor progression and therapeutic implications. It’s found that lncRNA AC093895.1 is highly expressed in OC tissues and correlated with poor prognosis. AC093895.1 has a potentiating effect during the progression and metastasis of ovarian cancer. The effects of AC093895.1 on ovarian cancer cells are miR-1253 dependent. Results showed that by interacting with tumor-suppressive gene miR-1253 as competing endogenous RNA (ceRNAs), AC093895.1 significantly upregulated the downstream gene SOX4 of AC093895.1/ miR-1253 axis, leading to tumor metastasis. In addition, chromatin immunoprecipitation (ChIP) results further confirmed that SOX4 could bind to the AC093895.1 promoter, forming a positive feedback loop SOX4/AC093895.1/miR-1253/SOX4. Therapeutic strategy to break the loop through AC093895.1 knockdown exhibited attenuated OC growth and metastasis in vivo both in SK-OV-3 subcutaneous model and pulmonary metastatic model. Our study unveiled the potentiating effects of SOX4/AC093895.1/miR-1253/SOX4 on ovarian cancer cell survival, migration, and invasion. AC093895.1 may be a promising patient prognostic biomarker and therapeutic candidate.